Skip to main content

eBioMedicine

  • ISSN: 2352-3964

Next planned ship date: May 22, 2024

  • 5 Year impact factor: 10
  • Impact factor: 11.1

For more information on the journal see https://www.thelancet.com/journals/ebiom/home eBioMedicine is the premium gold open access venue for translational biomedical r… Read more

Subscription options

Next planned ship date:
May 22, 2024

Institutional subscription on ScienceDirect

Request a sales quote
For more information on the journal see https://www.thelancet.com/journals/ebiom/home



eBioMedicine is the premium gold open access venue for translational biomedical research. The journal publishes original research that elucidates, or aims to modify, disease pathways and mechanisms—with the goal of advancing our knowledge in any biomedical discipline with relevance to human health as well as relevant reviews, commentaries, and opinion pieces. The journal prioritises papers investigating the basic determinants of human health and disease, the discovery and characterization of new therapeutic targets and treatments, and the identification of biomarkers and diagnostic tools which may help researchers and clinicians better understand and monitor disease.

eBioMedicine covers the whole spectrum of biomedical research, from preclinical studies with clear human relevance, through to proof-of-concept studies and clinical trials. The journal aspires to catalyse dialogue and collaboration between basic scientists, clinical researchers and healthcare professionals, enhance the accessibility and applicability of basic research findings for health professionals, and promote a better understanding of clinical challenges for biomedical researchers.